Lisdexamfetamine, sold under the brand name Vyvanse among others, is a stimulant medication that is mainly used to treat attention deficit hyperactivity disorder (ADHD) in people over the age of five as well as moderate-to-severe binge eating disorder in adults.
Lisdexamfetamine was approved for medical use in the United States in 2007. In 2019, it was the 79th most commonly prescribed medication in the United States, with more than 9 million prescriptions.
It has a high potential for substance abuse per the DEA. It is a scheduled II controlled substance in the United States.